Welcome to our dedicated page for Vaso news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on Vaso stock.
Vaso Corporation reports developments for a diversified medical technology business spanning network and IT services, professional sales services for medical equipment, and proprietary medical products. Company updates commonly cover operating results by segment, deferred revenue trends, gross profit, expenses, and the effect of portfolio changes such as the sale of its healthcare IT business unit.
Recurring news also includes subsidiary activity. VasoHealthcare represents GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments, while VasoMedical manages proprietary medical equipment and software and overseas assets, including China-based subsidiaries. Other updates address material agreements, shareholder meeting matters, and governance developments.
Vaso (OTCQX: VASO) reported Q1 2026 revenue of $19.4 million, down 0.5% year over year, but up 4.8% excluding a divested healthcare IT service business. Gross profit rose 1.9% to $11.6 million, while net loss narrowed to $887 thousand from $1.1 million.
Operating loss was $1.3 million and Adjusted EBITDA was negative $1.1 million. Operating cash outflow increased to $12.6 million, largely due to payment timing. Deferred revenue grew 11.6% to $39.5 million, and cash and equivalents were about $38.5 million on May 8, 2026.
Vaso Corporation (OTCQX: VASO) reported fiscal 2025 revenue of $89.1 million, up 2.7% year-over-year, and gross profit of $54.7 million (up 5%). Net income rose to $1.6 million and cash plus short-term investments reached $35.1 million as of December 31, 2025.
The company sold its healthcare IT business in November 2025, recorded a goodwill impairment, generated $9.3 million of operating cash flow, and saw deferred revenue increase to $38.6 million.
Vaso Corporation (OTCQX: VASO) announced that its subsidiary VasoHealthcare signed an amendment extending its sales representation agreement with GE HealthCare (NASDAQ: GEHC) through December 31, 2030. This marks the fifth extension of a partnership that began in May 2010, which will span over 20 years under the latest term.
Under the amendment, VasoHealthcare will continue representing GE HealthCare’s diagnostic imaging and ultrasound portfolio, including CT, MR, molecular imaging, X-ray, mammography, interventional solutions, plus related service and financial offerings, aiming to ensure continuity in sales representation and customer support nationwide.
Vaso Corporation (OTCQX: VASO) announced on November 19, 2025 that it reached an agreement, subject to conditions, to sell its subsidiary VasoHealthcare IT Corp. to Nano-X Imaging (Nasdaq: NNOX).
The buyer will pay up to $800,000 in total consideration: $200,000 at closing and up to $600,000 as an earnout tied to post-closing performance. VasoHealthcare IT represented less than 5% of Vaso’s total revenue. The parties intend to complete the sale within a couple of weeks. Vaso said it expects to use proceeds to invest in other business lines and strategic initiatives.
Vaso (OTCQX: VASO) reported third-quarter 2025 results for the three months ended September 30, 2025, with total revenue of $22.7 million, up 9.1% year‑over‑year. Gross profit rose to $13.9 million, an increase of 18.2%, and the company recorded net income of $1.7 million versus a net loss of $1.2 million in Q3 2024, a $2.9 million improvement. Adjusted EBITDA was $1.6 million versus negative $1.2 million a year earlier. Cash and cash equivalents were $34.9 million at quarter end, and operating cash flow for the first nine months of 2025 was $9.0 million versus $3.6 million in the prior-year period.
All three business segments contributed to revenue growth; professional sales services led with an 18.7% increase. SG&A rose modestly while deferred and subscription revenues continued to trend upward.
Vaso Corporation (OTCQX: VASO), a MedTech company, reported its Q2 2025 financial results with revenue of $20.0 million, slightly down 1.3% from $20.2 million in Q2 2024. The company posted a net loss of $197,000 compared to a net income of $1.2 million in the same period last year.
The company's professional sales service segment experienced a 4.0% decline, while the IT segment saw a 0.9% increase. Notable metrics include record-high deferred revenue of $38.1 million (up from $31.7 million YoY), gross profit of $11.8 million (down 2.9%), and strong cash position of $32.6 million. Operating cash flow for Q2 2025 was $6.8 million, demonstrating robust cash generation despite operational challenges.
The professional sales service segment saw a 7.1% revenue increase, while the IT segment grew by 1.6%. The equipment segment experienced a slight decline of 3.6%. Total deferred revenue reached $35.4 million, up 12.7% year-over-year, providing revenue stability and financial visibility.
The company maintained a strong balance sheet with $25.3 million in cash as of March 31, 2025, which improved to approximately $30.5 million by May 9, 2025. Despite increased market uncertainties, management remains cautiously optimistic about 2025, citing historically stronger performance in later quarters.
Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, up 7% year-over-year. The company's Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all business segments.
Key financial highlights for 2024:
- Gross profit increased 2.9% to $52.1 million
- Net income decreased to $1.0 million from $4.8 million in 2023
- Operating cash flow of $3.3 million
- Cash and equivalents of $26.3 million
- Deferred revenue grew 8% to $34.9 million
The decline in net income was primarily attributed to higher operating expenses, including investments in new programs and strategic activities. SG&A expenses increased 8.7% to $49.0 million, representing 56.5% of revenue.
Vaso (OTCQX: VASO) reported its Q4 and full-year 2024 financial results, achieving record annual revenue of $86.8 million, a 7% increase from 2023. Despite revenue growth, net income decreased to $1.3 million from $4.8 million in 2023 due to higher operating expenses.
Q4 2024 revenue increased 23.4% to $27.0 million, with growth across all segments: IT segment up 13.6% to $11.1 million, professional sales service up 31.2% to $15.0 million, and equipment segment up 31% to $921 thousand. The company maintained strong cash position with $26.3 million in cash and equivalents, while generating $3.3 million in operating cash flow during 2024.
Total deferred revenue grew 8% to $34.9 million, while adjusted EBITDA decreased to $1.4 million from $5.1 million in 2023. SG&A expenses increased 7.9% to $48.6 million, primarily due to higher personnel costs and expenses related to a terminated business combination transaction with Achari.
Vaso (OTCQX: VASO) announced key executive leadership changes effective January 1, 2025. Jane Moen, who has served as a Director since 2020, was appointed Chief Operating Officer while retaining her role as President of VasoHealthcare. Jonathan Newton was promoted to Chief Financial Officer from Co-Chief Financial Officer, with Michael Beecher transitioning to a financial and investor relations advisory role.
Additionally, Edgar Rios, who has served as an independent Director since 2011, was elected Vice Chairman of the Board of Directors and will continue as Chairman of the Board's Audit Committee. The company also appointed Kimberly Decker of Barley Snyder LLP as new corporate and securities outside counsel.
CEO Dr. Jun Ma emphasized these changes align with Vaso's human capital mission and 2025 strategy, focusing on organic growth across their diversified portfolio in human capital, MedTech, and information technology businesses.